Pınar Şişman1, Ahmet Bilgehan Şahin2, Hande Peynirci3, Soner Cander4, Özen Öz Gül4, Erdinç Ertürk4, Canan Ersoy4. 1. Clinic of Endocrinology and Metabolism, Harakani State Hospital, Kars, Turkey. 2. Department of Internal Medicine, Uludağ University School of Medicine, Bursa, Turkey. 3. Clinic of Endocrinology and Metabolism, Yusuf İslamoğlu State Hospital, Kastamonu, Turkey. 4. Department of Endocrinology and Metabolism, Uludağ University School of Medicine, Bursa, Turkey.
Abstract
OBJECTIVE: Adrenocortical carcinoma is an aggressive endocrine malignancy with an annual incidence of 0.5-2 cases per million. The most important factors that determine prognosis are tumor stage at the time of diagnosis and the success of surgery. However, advanced age, large tumor size, hormone secretion, high Ki-67 index (>10%), tumor necrosis and high mitotic activity are other factors associated with poor prognosis. In the present study, we aimed to evaluate the contribution of the patient and treatment- related factors to the prognosis in adrenocortical carcinoma. MATERIAL AND METHODS: We included 15 adrenocortical carcinoma patients who were followed in our center between 2005 and 2015. The effects of age, gender, tumor size, type of operation, postoperative resection status and adjuvant treatment on disease-free survival and overall survival were analyzed. RESULTS: Disease-free survival was 23.32±3.69 months and overall survival was 36.60±10.78 months. Gender, tumor size, tumor stage, type of operation, hormonal activity, presence of necrosis, recurrence and development of metastasis were not found to be associated with disease-free survival and overall survival (p>0.05). Postoperatively applied adjuvant treatments including mitotane, chemotherapy and radiotherapy did not significantly affect disease-free survival in our study, but statistically significant increase in overall survival was observed in patients getting adjuvant treatments (p=0.006). CONCLUSION: Adrenocortical carcinoma has poor prognosis and short overall survival, and in its clinical course, recurrence and development of metastasis can be commonly observed even after complete resection of the tumor. Therefore, the patients should be evaluated carefully while determining the surgical procedure during the preoperative period, and the operation and post-operative follow-up should be performed in experienced centers. However, due to the positive effects of adjuvant treatments on survival, all patients should be evaluated postoperatively for the necessity of adjuvant treatments, especially mitotane.
OBJECTIVE: Adrenocortical carcinoma is an aggressive endocrine malignancy with an annual incidence of 0.5-2 cases per million. The most important factors that determine prognosis are tumor stage at the time of diagnosis and the success of surgery. However, advanced age, large tumor size, hormone secretion, high Ki-67 index (>10%), tumor necrosis and high mitotic activity are other factors associated with poor prognosis. In the present study, we aimed to evaluate the contribution of the patient and treatment- related factors to the prognosis in adrenocortical carcinoma. MATERIAL AND METHODS: We included 15 adrenocortical carcinoma patients who were followed in our center between 2005 and 2015. The effects of age, gender, tumor size, type of operation, postoperative resection status and adjuvant treatment on disease-free survival and overall survival were analyzed. RESULTS: Disease-free survival was 23.32±3.69 months and overall survival was 36.60±10.78 months. Gender, tumor size, tumor stage, type of operation, hormonal activity, presence of necrosis, recurrence and development of metastasis were not found to be associated with disease-free survival and overall survival (p>0.05). Postoperatively applied adjuvant treatments including mitotane, chemotherapy and radiotherapy did not significantly affect disease-free survival in our study, but statistically significant increase in overall survival was observed in patients getting adjuvant treatments (p=0.006). CONCLUSION: Adrenocortical carcinoma has poor prognosis and short overall survival, and in its clinical course, recurrence and development of metastasis can be commonly observed even after complete resection of the tumor. Therefore, the patients should be evaluated carefully while determining the surgical procedure during the preoperative period, and the operation and post-operative follow-up should be performed in experienced centers. However, due to the positive effects of adjuvant treatments on survival, all patients should be evaluated postoperatively for the necessity of adjuvant treatments, especially mitotane.
Entities:
Keywords:
Adrenocortical carcinoma; chemotherapy; mitotane; surgery
Authors: A Berruti; E Baudin; H Gelderblom; H R Haak; F Porpiglia; M Fassnacht; G Pentheroudakis Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: David Brix; Bruno Allolio; Wiebke Fenske; Ayman Agha; Henning Dralle; Christian Jurowich; Peter Langer; Thomas Mussack; Christoph Nies; Hubertus Riedmiller; Martin Spahn; Dirk Weismann; Stefanie Hahner; Martin Fassnacht Journal: Eur Urol Date: 2010-06-22 Impact factor: 20.096
Authors: Shawn Sam Thomas; Arundhati Marathe; Anish Jacob Cherian; N Siddhartha; Gowri Mahasampath; Manipadam Marie Therese; Chandramohan Jagan; Hesarghatta Shyamasunder Asha; Nihal Thomas; Ashish Singh; B Selvamani; Mazhuvanchary Jacob Paul; Deepak Thomas Abraham Journal: Indian J Surg Oncol Date: 2021-09-13
Authors: Mohammad A Alghafees; Ziyad F Musalli; Khalaf Albaqami; Muhannad Q Alqirnas; Meshari A Alqahtani; Faisal Alrasheed; Ahmed Alasker Journal: Cureus Date: 2022-02-06
Authors: Rui Caetano Oliveira; Maria João Martins; Carolina Moreno; Rui Almeida; João Carvalho; Paulo Teixeira; Miguel Teixeira; Edgar Tavares Silva; Isabel Paiva; Arnaldo Figueiredo; Maria Augusta Cipriano Journal: Rare Tumors Date: 2021-06-27